Role of apoE structure and metabolism in neurodegeneration
Role of apoE structure and metabolism in neurodegeneration
批准号:
8235856
负责人:
ROBERT W. MAHLEY
金额:
$37.26万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2014-02-28
关键词:
AffectAgeAgingAlzheimer&aposs DiseaseAntibodiesApolipoprotein EApolipoproteinsAreaAstrocytesBehaviorBindingBiochemical PathwayBlood - brain barrier anatomyBrainCellsCerebrospinal FluidCholesterolCholesterol HomeostasisCognitive deficitsComplexCraniocerebral TraumaCrystallographyDataDegradation PathwayElectron Spin Resonance SpectroscopyEndoplasmic ReticulumEventFunctional disorderGene TargetingGoalsHealthHumanImpaired cognitionIndianaIschemiaKnock-in MouseLinkLipid BindingLipidsLipoproteinsLow Density Lipoprotein ReceptorMaintenanceMass Spectrum AnalysisMediatingMetabolismMicrogliaModelingMolecularMusMutationNerve DegenerationNeuraxisNeurodegenerative DisordersNeuronsOxidative StressPathway interactionsPhospholipidsPhysiologic pulsePlasmaPlayProcessProductionPropertyProtein ConformationProtein IsoformsProteinsProteolysisProteomicsQuality ControlRelative (related person)Research PersonnelResolutionReverse Transcriptase Polymerase Chain ReactionRiskRisk FactorsRoleShelter facilityStagingStressStructureSystemTestingTherapeuticTherapeutic InterventionToxic effectWild Type Mouseapolipoprotein E-3apolipoprotein E-4basebiological adaptation to stressdesignendoplasmic reticulum stressgenetic risk factorhigh riskimprovedinhibitor/antagonistinsightlipid metabolismlipid transportmouse modelneurotoxicnovelnovel therapeutic interventionparticleprotein expressionprotein foldingrepairedresponsestressorsynaptogenesistherapeutic targettwo-dimensional
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Apolipoprotein (apo) E plays a key role in lipid metabolism and transport in plasma and the central nervous system. One of the three major human apoE isoforms, apoE4, is a major risk factor for Alzheimer's disease by as yet undefined mechanisms. Our long-range objective is to employ a structure-function approach to establish these mechanisms with the goal of identifying potential therapeutic interventions. This proposal focuses on two major areas related to this goal. First, we will extend the resolution of our x-ray diffraction and small-angle x- ray scattering model of apoE4 bound to phospholipids and compare the structures of apoE4 and apoE3 bound to lipid. Secondly, we will continue our studies in which we link the apoE4 structural property of domain interaction to neurodegeneration and functional and cognitive deficits. The brains of human apoE isoform knock in mice and our Arg-61 apoE mouse model in which domain interaction was introduced, contain lower levels of apoE4 and Arg-61 mouse apoE compared to apoE3 and mouse wild-type apoE, respectively. The lower levels were due to decreased secretion by astrocytes, in which the Arg-61 apoE was selectively degraded, inducing an unfolded protein stress response. Based on these studies, we hypothesize that domain interaction contributes to neurodegeneration through two effects on astrocytes. 1) Domain interaction is recognized as an abnormally folded protein, resulting in an endoplasmic reticulum stress response that leads to downstream effects on key biochemical pathways supporting neuronal integrity. 2) Decreased secretion of apoE4 results in lower levels of cholesterol to support synapse formation and neuronal maintenance. This hypothesis represents a novel paradigm in which apoE4 domain interaction contributes to neurodegeneration and functional and cognitive deficits, involving astrocytes in the absence of additional stressors. We believe that these effects are early events in apoE4 carriers and set the stage for more dramatic responses with the addition of brain stressors (e.g. age, ischemia or A2 toxicity). This paradigm links apoE structure with neurodegeneration and functional consequences and suggests that interference with domain interaction is a viable therapeutic approach. These studies hold the potential to determine the mechanisms by which apoE4 is associated with a high risk for Alzheimer's disease and other forms of neurodegeneration and for identifying therapeutic approaches to reduce this risk. PUBLIC HEALTH RELEVANCE: Apolipoprotein E4 (apoE4) a brain protein, is the major genetic risk factor for Alzheimer's disease although the basis for this association is unknown. Based on our apoE4 structure studies, we propose a new mechanism for this association involving astrocytes, which are cells in the brain that support and maintain nerve cells. These studies hold the potential to identify new therapeutic approaches to reverse the effects of apoE4 on Alzheimer's disease.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approaches.
了解 apoE4 与阿尔茨海默氏病关联的基础:为治疗方法打开大门。
DOI:
10.2174/156720509789207921
发表时间:
2009
期刊:
Current Alzheimer research
影响因子:
2.1
作者:
[Zhong,Ning, Weisgraber,KarlH]
通讯作者:
Weisgraber,KarlH
DOI:
10.1161/atvbaha.116.307023
发表时间:
2016-07
期刊:
Arteriosclerosis, thrombosis, and vascular biology
影响因子:
--
作者:
[Mahley RW]
通讯作者:
Mahley RW
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.
载脂蛋白E:从心血管疾病到神经退行性疾病。
DOI:
10.1007/s00109-016-1427-y
发表时间:
2016-07
期刊:
Journal of molecular medicine (Berlin, Germany)
影响因子:
--
作者:
[Mahley RW]
通讯作者:
Mahley RW
DOI:
10.1194/jlr.d002493
发表时间:
2010-05
期刊:
Journal of lipid research
影响因子:
6.5
作者:
[Zhang L, Song J, Newhouse Y, Zhang S, Weisgraber KH, Ren G]
通讯作者:
Ren G
Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4
-
批准号:9893103
-
项目类别:
-
资助金额:$98.21万
-
财政年份:2019
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease
-
批准号:10056515
-
项目类别:
-
资助金额:$107.96万
-
财政年份:2019
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4
-
批准号:10011752
-
项目类别:
-
资助金额:$94.86万
-
财政年份:2019
-
负责人:ROBERT W. MAHLEY
-
依托单位:
ApoE4 Structure Correctors as a Therapeutic Approach for Alzheimers Disease
-
批准号:8460847
-
项目类别:
-
资助金额:$4.55万
-
财政年份:2012
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Targeting ApoE4 as a Therapeutic Strategy for Alzheimer's Disease
-
批准号:8549072
-
项目类别:
-
资助金额:$81.86万
-
财政年份:2012
-
负责人:ROBERT W. MAHLEY
-
依托单位:
ApoE4 Structure Correctors as a Therapeutic Approach for Alzheimers Disease
-
批准号:8328029
-
项目类别:
-
资助金额:$4.69万
-
财政年份:2012
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Targeting ApoE4 as a Therapeutic Strategy for Alzheimer's Disease
-
批准号:8420245
-
项目类别:
-
资助金额:$85.22万
-
财政年份:2012
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Role of apoE structure and metabolism in neurodegeneration
-
批准号:8036997
-
项目类别:
-
资助金额:$37.26万
-
财政年份:2008
-
负责人:ROBERT W. MAHLEY
-
依托单位:
APOLIPOPROTEIN E IN NEUROBIOLOGY: CELLULAR MECHANISMS
-
批准号:7431632
-
项目类别:
-
资助金额:$31.52万
-
财政年份:2007
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Targeting Apolipoprotein E4-related Neuropathology
-
批准号:6673321
-
项目类别:
-
资助金额:$21.26万
-
财政年份:2003
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Targeting Apolipoprotein E4-related Neuropathology
-
批准号:6752398
-
项目类别:
-
资助金额:$25.15万
-
财政年份:2003
-
负责人:ROBERT W. MAHLEY
-
依托单位:
EXTRAMULAR RESEARCH FACILITIES CONSTRUCTION
-
批准号:6718598
-
项目类别:
-
资助金额:$209.38万
-
财政年份:2003
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Genetic Determinants: Low HDL, High Triglycerides, Obes*
-
批准号:6637876
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2002
-
负责人:ROBERT W. MAHLEY
-
依托单位:
Genetic Determinants: Low HDL, High Triglycerides, Obes*
-
批准号:6535479
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2002
-
负责人:ROBERT W. MAHLEY
-
依托单位:
APOLIPOPROTEIN E ISOFORM EFFECTS IN TRANSGENIC ANIMALS
-
批准号:6496758
-
项目类别:
-
资助金额:$24.35万
-
财政年份:2001
-
负责人:ROBERT W. MAHLEY
-
依托单位:
CORE--METABOLISM AND PATHOLOGY
-
批准号:6496762
-
项目类别:
-
资助金额:$24.35万
-
财政年份:2001
-
负责人:ROBERT W. MAHLEY
-
依托单位:
CORE--METABOLISM AND PATHOLOGY
-
批准号:6353064
-
项目类别:
-
资助金额:$26.61万
-
财政年份:2000
-
负责人:ROBERT W. MAHLEY
-
依托单位:
APOLIPOPROTEIN E ISOFORM EFFECTS IN TRANSGENIC ANIMALS
-
批准号:6353060
-
项目类别:
-
资助金额:$26.61万
-
财政年份:2000
-
负责人:ROBERT W. MAHLEY
-
依托单位:
APOLIPOPROTEIN E ISOFORM EFFECTS IN TRANSGENIC ANIMALS
-
批准号:6202341
-
项目类别:
-
资助金额:$26.61万
-
财政年份:1999
-
负责人:ROBERT W. MAHLEY
-
依托单位:
CORE--METABOLISM AND PATHOLOGY
-
批准号:6202345
-
项目类别:
-
资助金额:$26.61万
-
财政年份:1999
-
负责人:ROBERT W. MAHLEY
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: